Tags

Type your tag names separated by a space and hit enter

Application Of Adoptive Immunotherapy In Ovarian Cancer.
Onco Targets Ther 2019; 12:7975-7991OT

Abstract

Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women's health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising results in many preclinical and clinical trials of OC. The application of ACT depends on different effector cells, such as lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cells. In this review, we focus on adoptive immunotherapies in ovarian cancer and summarize completed and ongoing preclinical/clinical trials. The future development directions and obstacles for ACT in OC treatment are discussed.

Authors+Show Affiliations

Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun 130061, China.Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun 130061, China.Department of Gynecological Oncology, The First Hospital of Jilin University, Changchun 130061, China.Department of Cancer Immunology, The First Hospital of Jilin University, Changchun 130061, China.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31632055

Citation

Yang, Siyu, et al. "Application of Adoptive Immunotherapy in Ovarian Cancer." OncoTargets and Therapy, vol. 12, 2019, pp. 7975-7991.
Yang S, Yin X, Yue Y, et al. Application Of Adoptive Immunotherapy In Ovarian Cancer. Onco Targets Ther. 2019;12:7975-7991.
Yang, S., Yin, X., Yue, Y., & Wang, S. (2019). Application Of Adoptive Immunotherapy In Ovarian Cancer. OncoTargets and Therapy, 12, pp. 7975-7991. doi:10.2147/OTT.S221773.
Yang S, et al. Application of Adoptive Immunotherapy in Ovarian Cancer. Onco Targets Ther. 2019;12:7975-7991. PubMed PMID: 31632055.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Application Of Adoptive Immunotherapy In Ovarian Cancer. AU - Yang,Siyu, AU - Yin,Xiaojiao, AU - Yue,Ying, AU - Wang,Siqing, Y1 - 2019/09/27/ PY - 2019/07/03/received PY - 2019/09/18/accepted PY - 2019/10/22/entrez PY - 2019/10/22/pubmed PY - 2019/10/22/medline KW - adoptive cell therapy KW - cancer immunotherapy KW - immune cells KW - ovarian cancer SP - 7975 EP - 7991 JF - OncoTargets and therapy JO - Onco Targets Ther VL - 12 N2 - Ovarian cancer (OC) has been the most fatal gynecological disease that threatens women's health. Surgery and platinum-based chemotherapy are the basic ovarian cancer treatments that can improve survival, but the five-year survival rate has not improved because of delayed diagnosis, drug resistance, and recurrence. Novel treatments are needed to improve the prognosis and survival rate of ovarian cancer patients. In recent years, adoptive cell therapy (ACT) has received increasing attention as an emerging therapeutic strategy in the treatment of solid tumors including OC. ACT has shown promising results in many preclinical and clinical trials of OC. The application of ACT depends on different effector cells, such as lymphokine-activated killer (LAK) cells, tumor-infiltrating lymphocytes (TILs), and genetically modified T cells. In this review, we focus on adoptive immunotherapies in ovarian cancer and summarize completed and ongoing preclinical/clinical trials. The future development directions and obstacles for ACT in OC treatment are discussed. SN - 1178-6930 UR - https://www.unboundmedicine.com/medline/citation/31632055/Application_Of_Adoptive_Immunotherapy_In_Ovarian_Cancer L2 - https://dx.doi.org/10.2147/OTT.S221773 DB - PRIME DP - Unbound Medicine ER -
Unbound Prime app for iOS iPhone iPadUnbound PubMed app for AndroidAlso Available:
Unbound MEDLINE
Unbound PubMed app for Windows